PEPD is a pivotal regulator of p53 tumor suppressor

被引:26
作者
Yang, Lu [1 ]
Li, Yun [1 ,2 ]
Bhattacharya, Arup [1 ]
Zhang, Yuesheng [1 ,3 ]
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Urol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA
来源
NATURE COMMUNICATIONS | 2017年 / 8卷
关键词
PROTEIN-PROTEIN INTERACTION; GROWTH-FACTOR RECEPTOR; PROLINE-RICH DOMAIN; PROLIDASE DEFICIENCY; SH3; DOMAIN; EXPRESSION; APOPTOSIS; ENZYME; TRANSACTIVATION; CHEMOTHERAPY;
D O I
10.1038/s41467-017-02097-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
p53 tumor suppressor responds to various cellular stresses and regulates cell fate. Here, we show that peptidase D (PEPD) binds and suppresses over half of nuclear and cytoplasmic p53 under normal conditions, independent of its enzymatic activity. Eliminating PEPD causes cell death and tumor regression due to p53 activation. PEPD binds to the proline-rich domain in p53, which inhibits phosphorylation of nuclear p53 and MDM2-mediated mitochondrial translocation of nuclear and cytoplasmic p53. However, the PEPD-p53 complex is critical for p53 response to stress, as stress signals doxorubicin and H2O2 each must free p53 from PEPD in order to achieve robust p53 activation, which is mediated by reactive oxygen species. Thus, PEPD stores p53 for the stress response, but this also renders cells dependent on PEPD for survival, as it suppresses p53. This finding provides further understanding of p53 regulation and may have significant implications for the treatment of cancer and other diseases.
引用
收藏
页数:15
相关论文
共 59 条
  • [51] The mitochondrial p53 pathway
    Vaseva, Angelina V.
    Moll, Ute M.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2009, 1787 (05): : 414 - 420
  • [52] The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression
    Venot, C
    Maratrat, M
    Dureuil, C
    Conseiller, E
    Bracco, L
    Debussche, L
    [J]. EMBO JOURNAL, 1998, 17 (16) : 4668 - 4679
  • [53] Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth
    Yang, L.
    Li, Y.
    Zhang, Y.
    [J]. CELL DEATH & DISEASE, 2014, 5 : e1211 - e1211
  • [54] Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D
    Yang, Lu
    Li, Yun
    Bhattacharya, Arup
    Zhang, Yuesheng
    [J]. ONCOTARGET, 2016, 7 (27) : 42340 - 42352
  • [55] A plasma proteolysis pathway comprising blood coagulation proteases
    Yang, Lu
    Li, Yun
    Bhattacharya, Arup
    Zhang, Yuesheng
    [J]. ONCOTARGET, 2016, 7 (27) : 40919 - 40938
  • [56] Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant
    Yang, Lu
    Li, Yun
    Bhattacharya, Arup
    Zhang, Yuesheng
    [J]. EBIOMEDICINE, 2015, 2 (05): : 396 - 405
  • [57] Prolidase Directly Binds and Activates Epidermal Growth Factor Receptor and Stimulates Downstream Signaling
    Yang, Lu
    Li, Yun
    Ding, Yi
    Choi, Kyoung-Soo
    Kazim, A. Latif
    Zhang, Yuesheng
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (04) : 2365 - 2375
  • [58] The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response
    Zheng, HW
    You, H
    Zhou, XZ
    Murray, SA
    Uchida, T
    Wulf, G
    Gu, L
    Tang, XR
    Lu, KP
    Xiao, ZXJ
    [J]. NATURE, 2002, 419 (6909) : 849 - 853
  • [59] The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation
    Zilfou, JT
    Hoffman, WH
    Sank, M
    George, DL
    Murphy, M
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (12) : 3974 - 3985